Jump Financial LLC Trims Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Jump Financial LLC reduced its stake in Ultragenyx Pharmaceutical by 76.5%, owning 26,515 shares worth approximately $960,000 after selling 86,301 shares.
• Overall, 97.67% of Ultragenyx Pharmaceutical's stock is held by institutional investors, with several firms recently increasing their positions.
• Ultragenyx reported a quarterly revenue of $166.50 million, exceeding analyst estimates, but still posted a loss of ($1.17) EPS.

Jump Financial LLC cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 76.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,515 shares of the biopharmaceutical company's stock after selling 86,301 shares during the period. Jump Financial LLC's holdings in Ultragenyx Pharmaceutical were worth $960,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RARE. GAMMA Investing LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares in the last quarter. ANTIPODES PARTNERS Ltd acquired a new stake in Ultragenyx Pharmaceutical in the first quarter valued at approximately $57,000. Headlands Technologies LLC acquired a new stake in Ultragenyx Pharmaceutical in the first quarter valued at approximately $59,000. Covestor Ltd boosted its stake in Ultragenyx Pharmaceutical by 86.8% in the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock valued at $62,000 after acquiring an additional 795 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $82,000. 97.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Wells Fargo & Company lowered their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. HC Wainwright upgraded shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price for the company in a research note on Monday, July 28th. Canaccord Genuity Group lowered their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Guggenheim restated a "buy" rating and issued a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Finally, Wedbush decreased their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a report on Monday, July 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of "Moderate Buy" and an average target price of $81.50.

Insider Buying and Selling

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the sale, the director owned 15,344 shares in the company, valued at approximately $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 1.1%

Shares of NASDAQ RARE traded down $0.34 during midday trading on Monday, reaching $29.96. The company had a trading volume of 1,340,019 shares, compared to its average volume of 1,472,288. The business's 50-day simple moving average is $30.83 and its 200 day simple moving average is $35.06. The stock has a market cap of $2.89 billion, a P/E ratio of -5.42 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 1 year low of $25.81 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. During the same quarter last year, the company posted ($1.52) earnings per share. The firm's revenue was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.